エイリアス: ラロキシフェン塩酸塩; KEOXIFENE
CAS: 82640-04-8
純度: 99%
MF: C28H28ClNO4S
MW: 510.04
外観: 淡黄色の粉末
関連物質: 医薬品グレード
ストレージ: シェーディング, 密閉保存
Raloxifen hydrochloride, a second-generation Selective Estrogen Receptor Modulator (サーム) in the Raloxifene hydrochloride benzothiophene family. On September 13, 2007, the U. S. Food and Drug Administration approved Evista for reduction in the risk of invasive breast cancer in postmenopausal women with and Raloxifene hydrochloride without osteoporosis. It has also been approved as a potent stand-alone osteoporosis treatment.
Raloxifene is used to prevent and treat osteoporosis (condition in which the bones become thin and weak and break easily) in women have undergone menopause. Raloxifene is also used to decrease the risk of developing invasive breast cancer (breast cancer that has spread outside of the milk ducts or lobules into the surrounding breast tissue).
Raloxifene prevents and treats osteoporosis by mimicking the effects of estrogen (a female hormone produced by the body) to increase the density (thickness) of bone. Raloxifene decreases the risk of developing invasive breast cancer by blocking the effects of estrogen on breast tissue. This may stop the development of tumors that need estrogen to grow.
| 試験項目 |
仕様 |
試験結果 |
| 外観 |
Yellowish powder |
Comply |
| 識別 |
Ir |
Comply |
|
It meets the requirements of the test for choride |
Comply |
| 溶解性 |
に溶ける 10% 水酸化ナトリウム溶液,
slightly soluble in methanol,insoluble in water |
Comply |
| アッセイ |
98.5%~101.5% |
99.15% |
| 関連物質 |
Rrt=0.74 impurity |
≤0.20% |
Comply |
|
Other single impurity |
≤0.10% |
0.07% |
|
総不純物 |
≤0.5% |
0.26% |
| 乾燥減量 |
≤0.5% |
0.10% |
| 強熱時の残留物 |
≤0.1% |
Comply |
| 重金属 |
≤10ppm |
Comply |
| ストレージ |
Preserve in well-closed containers and protected from light.Store at room temperature. |
| 結論 |
Complies with usp32 standard |
